Related Experiment Video

Updated: Aug 14, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Economic evaluation of pneumococcal conjugate vaccination in Finland

Heini Salo1, Harri Sintonen, J Pekka Nuorti

  • 1Department of Vaccines, National Public Health Institute (KTL), Helsinki, Finland. heini.salo@ktl.fi

Scandinavian Journal of Infectious Diseases
|November 26, 2005
PubMed

Insights

Pneumococcal conjugate vaccine (PCV7) is cost-effective for children under 5, preventing numerous illnesses and deaths. Vaccination investment yields significant savings in medical and societal costs.

Area of Science:

  • Pediatrics
  • Public Health
  • Health Economics

Background:

  • Pneumococcal conjugate vaccine (PCV7) prevents serious pneumococcal diseases.
  • Cost-effectiveness of PCV7 in young children requires evaluation.

Purpose of the Study:

  • To assess the cost-effectiveness of PCV7 vaccination in children under 5 years of age.
  • To analyze the direct economic impact of PCV7 on healthcare and societal costs.

Main Methods:

  • A Markov simulation model was employed to compare PCV7 vaccination with no intervention.
  • The analysis considered direct effects of the vaccine, including disease prevention and cost savings.

Main Results:

  • Vaccinating a birth cohort of 57,500 infants in Finland could prevent 60 invasive pneumococcal disease cases, 1,400 pneumococcal pneumonia cases, 15,000 acute otitis media episodes, 3,000 surgeries, and 0.9 deaths annually.
  • An investment of 12.0 million euros for vaccination could result in annual savings of 6.3 million euros in medical costs and 2.0 million euros in productivity and other costs.
  • Each euro invested in the PCV7 vaccination program could return 0.53 euros in medical cost savings and 0.70 euros in societal cost savings.

Conclusions:

  • PCV7 vaccination is a cost-effective intervention for children under 5, offering substantial medical and societal economic benefits.
  • To ensure cost savings from a healthcare provider perspective, the price of PCV7 would need to be reduced significantly.

More Related Videos

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines05:39

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: